Medical Care

Global Biosynthesis Peptide Drugs Market Research Report 2025

The global market for Biosynthesis Peptide Drugs was valued at US$ 18270 million in the year 2024 and is projected to reach a revised size of US$ 27670 million by 2031, growing at a CAGR of 6.2% during the forecast period.
Biosynthesis peptide drugs refer to pharmaceuticals that are produced using biotechnology and genetic engineering techniques. These drugs are created by synthesizing peptides through living organisms, such as bacteria, yeast, or mammalian cells, which have been genetically modified to express specific peptide sequences. This approach allows for the large-scale production of complex and bioactive peptides.
Biosynthesis peptide drugs are a prominent segment in today"s pharmaceutical industry. The market size is steadily expanding, with significant growth in sales, primarily used in the treatment of various diseases such as diabetes, cancer, and immune-related disorders. These drugs mimic naturally occurring peptides in the body, exerting unique therapeutic effects on specific diseases. Future development trends indicate ongoing innovation in the field of biosynthesis peptide drugs, with the potential emergence of more efficient and precise treatment options, contributing to the continuous advancement of medical technology.
This report aims to provide a comprehensive presentation of the global market for Biosynthesis Peptide Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosynthesis Peptide Drugs.
The Biosynthesis Peptide Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosynthesis Peptide Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosynthesis Peptide Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novo Nordisk
AstraZeneca
Eli Lily
Sanofi
Segment by Type
Dulaglutide
Semaglutide
Insulin Glargine
Insulin Aspart
Liraglutide
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosynthesis Peptide Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosynthesis Peptide Drugs Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Dulaglutide
1.2.3 Semaglutide
1.2.4 Insulin Glargine
1.2.5 Insulin Aspart
1.2.6 Liraglutide
1.3 Market by Application
1.3.1 Global Biosynthesis Peptide Drugs Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosynthesis Peptide Drugs Market Perspective (2020-2031)
2.2 Global Biosynthesis Peptide Drugs Growth Trends by Region
2.2.1 Global Biosynthesis Peptide Drugs Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Biosynthesis Peptide Drugs Historic Market Size by Region (2020-2025)
2.2.3 Biosynthesis Peptide Drugs Forecasted Market Size by Region (2026-2031)
2.3 Biosynthesis Peptide Drugs Market Dynamics
2.3.1 Biosynthesis Peptide Drugs Industry Trends
2.3.2 Biosynthesis Peptide Drugs Market Drivers
2.3.3 Biosynthesis Peptide Drugs Market Challenges
2.3.4 Biosynthesis Peptide Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosynthesis Peptide Drugs Players by Revenue
3.1.1 Global Top Biosynthesis Peptide Drugs Players by Revenue (2020-2025)
3.1.2 Global Biosynthesis Peptide Drugs Revenue Market Share by Players (2020-2025)
3.2 Global Biosynthesis Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biosynthesis Peptide Drugs Revenue
3.4 Global Biosynthesis Peptide Drugs Market Concentration Ratio
3.4.1 Global Biosynthesis Peptide Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosynthesis Peptide Drugs Revenue in 2024
3.5 Global Key Players of Biosynthesis Peptide Drugs Head office and Area Served
3.6 Global Key Players of Biosynthesis Peptide Drugs, Product and Application
3.7 Global Key Players of Biosynthesis Peptide Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosynthesis Peptide Drugs Breakdown Data by Type
4.1 Global Biosynthesis Peptide Drugs Historic Market Size by Type (2020-2025)
4.2 Global Biosynthesis Peptide Drugs Forecasted Market Size by Type (2026-2031)
5 Biosynthesis Peptide Drugs Breakdown Data by Application
5.1 Global Biosynthesis Peptide Drugs Historic Market Size by Application (2020-2025)
5.2 Global Biosynthesis Peptide Drugs Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Biosynthesis Peptide Drugs Market Size (2020-2031)
6.2 North America Biosynthesis Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Biosynthesis Peptide Drugs Market Size by Country (2020-2025)
6.4 North America Biosynthesis Peptide Drugs Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosynthesis Peptide Drugs Market Size (2020-2031)
7.2 Europe Biosynthesis Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Biosynthesis Peptide Drugs Market Size by Country (2020-2025)
7.4 Europe Biosynthesis Peptide Drugs Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosynthesis Peptide Drugs Market Size (2020-2031)
8.2 Asia-Pacific Biosynthesis Peptide Drugs Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Biosynthesis Peptide Drugs Market Size by Region (2020-2025)
8.4 Asia-Pacific Biosynthesis Peptide Drugs Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosynthesis Peptide Drugs Market Size (2020-2031)
9.2 Latin America Biosynthesis Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Biosynthesis Peptide Drugs Market Size by Country (2020-2025)
9.4 Latin America Biosynthesis Peptide Drugs Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosynthesis Peptide Drugs Market Size (2020-2031)
10.2 Middle East & Africa Biosynthesis Peptide Drugs Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Biosynthesis Peptide Drugs Market Size by Country (2020-2025)
10.4 Middle East & Africa Biosynthesis Peptide Drugs Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Details
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Biosynthesis Peptide Drugs Introduction
11.1.4 Novo Nordisk Revenue in Biosynthesis Peptide Drugs Business (2020-2025)
11.1.5 Novo Nordisk Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Details
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Biosynthesis Peptide Drugs Introduction
11.2.4 AstraZeneca Revenue in Biosynthesis Peptide Drugs Business (2020-2025)
11.2.5 AstraZeneca Recent Development
11.3 Eli Lily
11.3.1 Eli Lily Company Details
11.3.2 Eli Lily Business Overview
11.3.3 Eli Lily Biosynthesis Peptide Drugs Introduction
11.3.4 Eli Lily Revenue in Biosynthesis Peptide Drugs Business (2020-2025)
11.3.5 Eli Lily Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Biosynthesis Peptide Drugs Introduction
11.4.4 Sanofi Revenue in Biosynthesis Peptide Drugs Business (2020-2025)
11.4.5 Sanofi Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Biosynthesis Peptide Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Dulaglutide
Table 3. Key Players of Semaglutide
Table 4. Key Players of Insulin Glargine
Table 5. Key Players of Insulin Aspart
Table 6. Key Players of Liraglutide
Table 7. Global Biosynthesis Peptide Drugs Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Biosynthesis Peptide Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Biosynthesis Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Biosynthesis Peptide Drugs Market Share by Region (2020-2025)
Table 11. Global Biosynthesis Peptide Drugs Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Biosynthesis Peptide Drugs Market Share by Region (2026-2031)
Table 13. Biosynthesis Peptide Drugs Market Trends
Table 14. Biosynthesis Peptide Drugs Market Drivers
Table 15. Biosynthesis Peptide Drugs Market Challenges
Table 16. Biosynthesis Peptide Drugs Market Restraints
Table 17. Global Biosynthesis Peptide Drugs Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Biosynthesis Peptide Drugs Market Share by Players (2020-2025)
Table 19. Global Top Biosynthesis Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosynthesis Peptide Drugs as of 2024)
Table 20. Ranking of Global Top Biosynthesis Peptide Drugs Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Biosynthesis Peptide Drugs Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Biosynthesis Peptide Drugs, Headquarters and Area Served
Table 23. Global Key Players of Biosynthesis Peptide Drugs, Product and Application
Table 24. Global Key Players of Biosynthesis Peptide Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Biosynthesis Peptide Drugs Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Biosynthesis Peptide Drugs Revenue Market Share by Type (2020-2025)
Table 28. Global Biosynthesis Peptide Drugs Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Biosynthesis Peptide Drugs Revenue Market Share by Type (2026-2031)
Table 30. Global Biosynthesis Peptide Drugs Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Biosynthesis Peptide Drugs Revenue Market Share by Application (2020-2025)
Table 32. Global Biosynthesis Peptide Drugs Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Biosynthesis Peptide Drugs Revenue Market Share by Application (2026-2031)
Table 34. North America Biosynthesis Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Biosynthesis Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Biosynthesis Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Biosynthesis Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Biosynthesis Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Biosynthesis Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Biosynthesis Peptide Drugs Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Biosynthesis Peptide Drugs Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Biosynthesis Peptide Drugs Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Biosynthesis Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Biosynthesis Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Biosynthesis Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Biosynthesis Peptide Drugs Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Biosynthesis Peptide Drugs Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Biosynthesis Peptide Drugs Market Size by Country (2026-2031) & (US$ Million)
Table 49. Novo Nordisk Company Details
Table 50. Novo Nordisk Business Overview
Table 51. Novo Nordisk Biosynthesis Peptide Drugs Product
Table 52. Novo Nordisk Revenue in Biosynthesis Peptide Drugs Business (2020-2025) & (US$ Million)
Table 53. Novo Nordisk Recent Development
Table 54. AstraZeneca Company Details
Table 55. AstraZeneca Business Overview
Table 56. AstraZeneca Biosynthesis Peptide Drugs Product
Table 57. AstraZeneca Revenue in Biosynthesis Peptide Drugs Business (2020-2025) & (US$ Million)
Table 58. AstraZeneca Recent Development
Table 59. Eli Lily Company Details
Table 60. Eli Lily Business Overview
Table 61. Eli Lily Biosynthesis Peptide Drugs Product
Table 62. Eli Lily Revenue in Biosynthesis Peptide Drugs Business (2020-2025) & (US$ Million)
Table 63. Eli Lily Recent Development
Table 64. Sanofi Company Details
Table 65. Sanofi Business Overview
Table 66. Sanofi Biosynthesis Peptide Drugs Product
Table 67. Sanofi Revenue in Biosynthesis Peptide Drugs Business (2020-2025) & (US$ Million)
Table 68. Sanofi Recent Development
Table 69. Research Programs/Design for This Report
Table 70. Key Data Information from Secondary Sources
Table 71. Key Data Information from Primary Sources
Table 72. Authors List of This Report


List of Figures
Figure 1. Biosynthesis Peptide Drugs Picture
Figure 2. Global Biosynthesis Peptide Drugs Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Biosynthesis Peptide Drugs Market Share by Type: 2024 VS 2031
Figure 4. Dulaglutide Features
Figure 5. Semaglutide Features
Figure 6. Insulin Glargine Features
Figure 7. Insulin Aspart Features
Figure 8. Liraglutide Features
Figure 9. Global Biosynthesis Peptide Drugs Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Biosynthesis Peptide Drugs Market Share by Application: 2024 VS 2031
Figure 11. Hospital Case Studies
Figure 12. Clinic Case Studies
Figure 13. Other Case Studies
Figure 14. Biosynthesis Peptide Drugs Report Years Considered
Figure 15. Global Biosynthesis Peptide Drugs Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Biosynthesis Peptide Drugs Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Biosynthesis Peptide Drugs Market Share by Region: 2024 VS 2031
Figure 18. Global Biosynthesis Peptide Drugs Market Share by Players in 2024
Figure 19. Global Top Biosynthesis Peptide Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosynthesis Peptide Drugs as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Biosynthesis Peptide Drugs Revenue in 2024
Figure 21. North America Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Biosynthesis Peptide Drugs Market Share by Country (2020-2031)
Figure 23. United States Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Biosynthesis Peptide Drugs Market Share by Country (2020-2031)
Figure 27. Germany Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Biosynthesis Peptide Drugs Market Share by Region (2020-2031)
Figure 35. China Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Biosynthesis Peptide Drugs Market Share by Country (2020-2031)
Figure 43. Mexico Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Biosynthesis Peptide Drugs Market Share by Country (2020-2031)
Figure 47. Turkey Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Biosynthesis Peptide Drugs Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Novo Nordisk Revenue Growth Rate in Biosynthesis Peptide Drugs Business (2020-2025)
Figure 51. AstraZeneca Revenue Growth Rate in Biosynthesis Peptide Drugs Business (2020-2025)
Figure 52. Eli Lily Revenue Growth Rate in Biosynthesis Peptide Drugs Business (2020-2025)
Figure 53. Sanofi Revenue Growth Rate in Biosynthesis Peptide Drugs Business (2020-2025)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies